Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Hyperuricemia 3Tumor Lysis Syndrome 2Lymphoma 2Leukemia 2Sarcoma, Alveolar Soft Part 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Inflammation 1Gout 1Chondrosarcoma 1Cardiovascular Diseases 1Arthritis 1

Interventions

rasburicase 3Urate Oxidase 3Febuxostat 2Allopurinol 2venetoclax 1obinutuzumab 1Lenalidomide 1Bendamustine Hydrochloride 1AZD0466 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Tumor Lysis Syndrome × Allopurinol × Clear all
NCT01724528 2014-11-03

FLORENCE

Menarini Group

Phase 3 Completed
346 enrolled 16 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡